July 27, 2017 6:16 AM ET


Company Overview of H3 Biomedicine Inc.

Company Overview

H3 Biomedicine Inc., a biopharmaceutical company, is engaged in the discovery and development of small-molecule drugs to treat cancer. H3 Biomedicine Inc. has a strategic collaboration with Selvita S.A. The company was founded in 2010 and is based in Cambridge, Massachusetts. H3 Biomedicine Inc. operates as a subsidiary of Eisai Inc.

300 Technology Square

Fifth Floor

Cambridge, MA 02139

United States

Founded in 2010



Key Executives for H3 Biomedicine Inc.

Chief Executive Officer and President
Scientific Founder
Age: 61
Scientific Founder
Senior Vice President of Planning and Operations
Chief Data Sciences Officer
Compensation as of Fiscal Year 2017.

H3 Biomedicine Inc. Key Developments

H3 Biomedicine Inc. Report Preclinical Data Describing Immune Evasion Mechanism in Muscle-Invasive Bladder Cancer

H3 Biomedicine Inc. announced that data on one of H3’s pre-clinical programs focusing on muscle-invasive bladder cancer, has been published in the current issue of Nature Communications. Muscle-invasive bladder cancer is an aggressive form of cancer with limited therapeutic options available to patients. In the past year, agents designed to target the immune system have been approved for bladder cancer; however, the median survival in patients with second-line disease remains less than a year, and less than a third of first-line patients respond to treatment. Based on this unmet need, researchers at H3 Biomedicine took a novel approach to understanding how tumors can overcome the debilitating effects of the immune system. The publication in Nature Communications reports that a significant proportion of bladder tumors showing focal amplification of PPAR? and hotspot mutations in RXRa, lead to hyperactivity of the peroxisome proliferator-activated receptor gamma (PPAR?) pathway. Deep molecular characterization in cell lines and clinical samples also showed that tumors increased the activity of this pathway to prevent immune cells from infiltrating the tumors increasing the survival of the tumor cells. In collaboration with a team of Drs. Mads Daugaard and Peter Black at the University of British Columbia, the Vancouver Prostate Centre and VCHRI, the scientists further confirmed the association of PPAR? pathway activity with immune evasion in additional cohorts of bladder tumors.

H3 Biomedicine Inc. Appoints Lihua Yu as Chief Data Sciences Officer

H3 Biomedicine Inc. announced that Lihua Yu, Ph.D., has been promoted to Chief Data Sciences Officer. Dr. Yu previously served as the company’s Vice President, Data Science and Information Technology. In her new role, Yu willoversee the company’s computational biology and data mining activities, including the management of the company’s cancer genomics and pharmacogenomics data. Additionally, she will supervise the identification and integration of all data analysis capabilities for discovery, preclinical and clinical data. Yu will also lead the Discovery Informatics team in developing genomics data management, integration, and exploration solutions to enable data mining and utilization across the company. Dr. Yu has over 17 years of experience in computational biology and bioinformatics, as well as deep knowledge in the area of cancer genomics and predictive biomarkers. Before joining the company in 2011, Dr. Yu spent 12 years with AstraZeneca’s research and development unit, helping to build and deliver the multinational pharmaceutical company’s oncology bioinformatics capabilities.

H3 Biomedicine Announces Appointment of Peter G. Smith, Ph. D., as Chief Scientific Officer

H3 Biomedicine Inc. announced that Peter G. Smith, Ph.D., will become the company’s chief scientific officer, effective March 1, 2017. Dr. Smith transitions to his new position from vice president, Drug Discovery Biology. In his role as chief scientific officer, Dr. Smith will be responsible for setting the scientific strategy and priorities for H3 Biomedicine, as well as overseeing day-to-day research operations. Dr. Smith joined H3 Biomedicine in 2011 as the director of Target Biology, and soon advanced to the position of vice president, Drug Discovery Biology.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact H3 Biomedicine Inc., please visit www.h3biomedicine.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.